ChiCTR2000034176 版本V1.0 版本创建时间2020/06/27 14:37:58 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000034176 

最近更新日期:

Date of Last Refreshed on:

2020-06-27 14:37:54 

注册时间:

Date of Registration:

1990-01-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

肿瘤患者骨骼肌指数变化量与生存预后关系的回顾性分析

Public title:

A retrospective analysis of the relationship between skeletal muscle index changes and survival prognosis in tumor patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肿瘤患者骨骼肌指数变化量与生存预后关系的回顾性分析

Scientific title:

A retrospective analysis of the relationship between skeletal muscle index changes and survival prognosis in tumor patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

余伊榄 

研究负责人:

陈凌翔 

Applicant:

Yilan Yu 

Study leader:

Linxiang Chen 

申请注册联系人电话:

Applicant telephone:

15250962227

研究负责人电话:

Study leader's telephone:

13901599520

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15250962227@163.com

研究负责人电子邮件:

Study leader's E-mail:

bg4wfc@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市栖霞区

研究负责人通讯地址:

江苏省南京市玄武区百子亭42号 江苏省肿瘤医院

Applicant address:

Qixia District, Nanjing, Jiangsu, China

Study leader's address:

42 Baiziting street, Xuanwu District, Nanjing, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

东曜药业股份有限公司

Applicant's institution:

TOT BIOPHARM

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

江苏省肿瘤医院伦理委员会2020科-030

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

江苏省肿瘤医院伦理委员会

Name of the ethic committee:

thics Committee of Jiangsu Cancer Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

鲍军

Contact Name of the ethic committee:

Jun Bao

伦理委员会联系地址:

江苏省南京市玄武区百子亭42号 江苏省肿瘤医院

Contact Address of the ethic committee:

42 Baiziting street, Xuanwu District, Nanjing, Jiangsu, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省肿瘤医院

Primary sponsor:

Jiangsu Cancer Hospital

研究实施负责(组长)单位地址:

江苏省南京市玄武区百子亭42号

Primary sponsor's address:

42 Baiziting street, Xuanwu District, Nanjing, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省肿瘤医院

具体地址:

玄武区百子亭42号

Institution
hospital:

Jiangsu Cancer Hospital

Address:

42 Baiziting Street, Xuanwu District

经费或物资来源:

Source(s) of funding:

nothing

Target disease:

Cancer

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

单臂 

Study design:

Single arm 

研究目的:

通过回顾性收集晚期胃癌及贲门癌患者腹部CT测定患者腰三椎位置骨骼肌指数,判定患者骨骼肌指数变化量,从而判断消化道肿瘤患者骨骼肌指数、BMI、体重变化量与生存预后关系。  

Objectives of Study:

By retrospectively collecting abdominal CT of patients with advanced gastric cancer and cardia cancer, the skeletal muscle index of the lumbar trivertebral position of the patients was measured to determine the changes in the skeletal muscle indexes of the patients and the relationship between the changes in skeletal muscle index, BMI, body weight and survival prognosis of patients with gastrointestinal tumors.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 晚期胃癌及贲门癌患者;
2. 有不小于3次间隔均匀的腹部CT结果
3. 有不小于3次间隔均匀的身高、体重、实验室检查(血常规、血生化)结果(与CT时间差不超过7天)。

Inclusion criteria

1. Patients with advanced gastric cancer and cardiac cancer;
2. There are not less than 3 times of abdominal CT results evenly spaced
3. There are not less than 3 times of uniform height, weight, and laboratory examination (blood routine, blood biochemical) results (with CT time difference not more than 7 days).

排除标准:

1. 经医师判断不可纳入的患者

Exclusion criteria:

1. Patients who cannot be included in the judgment of the doctor

研究实施时间:

Study execute time:

From 2020-07-06 00:00:00 To 2020-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-07-06 00:00:00 To 2020-08-07 00:00:00  

干预措施:

Interventions:

组别:

case series

样本量:

30

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China 

Province:

Jiangsu 

City:

Nanjing 

单位(医院):

江苏省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Jiangsu Cancer Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

腰三椎骨骼肌指数

指标类型:

主要指标

Outcome:

Skeletal muscle index at the third lumbar vertebra

Type:

Primary indicator

测量时间点:

测量方法:

CT骨骼肌面积测量

Measure time point of outcome:

Measure method:

Skeletal muscle area measurement from CT

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 39 years
最大 Max age 81 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

nothing

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2020.11.30,中国临床试验注册中心网络平台:http://www.chictr.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2020.11.30, Network platform, China clinical trial registration center:http://www.chictr.org.cn/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

没有说明

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

no state

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2020-06-27 14:37:54